Medical Devices

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

05/31/2023

-FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response -FLX475 modifies the tumor microenvironment (TME) to resemble those of responders to anti-PD(L)1 monotherapy Excerpt from the Press Release: RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients…

Read More

JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice

02/01/2023

Guide Helps Transplant Centers Continue the Evolution from Endomyocardial Biopsies to Noninvasive Surveillance Using AlloMap GEP and AlloSure dd-cfDNA Excerpt from the Press Release: BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that…

Read More

IntraOp and Vanderbilt University Medical Center Announce First Patient Treated for Pancreatic Cancer Using Intra-Operative Radiation Therapy With Electrons

01/24/2023

IntraOp MobetronProves An Effective Tool In This First-Time Pancreatic Treatment at VUMC Excerpt from the Press Release: SUNNYVALE, Calif.–(BUSINESS WIRE)–IntraOp Medical Corporation announced today that doctors at Vanderbilt University Medical Center (VUMC) treated a pancreatic cancer patient using IntraOp® Mobetron® Intra-Operative Radiation Therapy (IORT). Based in Nashville, Tennessee, and serving the southeast region of the…

Read More

Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies

01/17/2023

FMC-376 directly, rapidly, and completely blocks both active and inactive forms of KRASG12C to overcome non-response and resistance seen with prior generation KRASG12C inhibitors The company has also advanced two additional precision oncology programs against historically undruggable disease-causing targets into lead optimization Pamela Klein, M.D., seasoned oncology drug developer, elected to board of directors Excerpt…

Read More

Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

01/13/2023

As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trialA supportive analysis using consensus reads of digitized biopsy images by the central pathologists replicated the positive primary endpoint resultsThese data will be presented at the NASH-TAG Conference on Friday January 6th, 2023 Excerpt from…

Read More

Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis

01/12/2023

Excerpt from the Press Release: PTAP Lowers the Cost of PoNS Therapy™ for Qualified Americans NEWTOWN, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) — Helius Medical Technologies (NASDAQ: HSDT) today announced the extension of a program that puts the company’s Portable Neuromodulation Stimulator (PoNS®) into the hands of qualified Americans with multiple sclerosis (MS) at a…

Read More

NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway

12/09/2022

First patient receives brain-responsive neuromodulation for LGS, a severe and disabling childhood-onset epilepsy Excerpt from the Press Release: MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that the first patient with Lennox-Gastaut Syndrome (LGS) was treated in its feasibility…

Read More

Biological Dynamics collaborates on clinical utility studies to examine the impact of its early pancreatic cancer detection assay

11/29/2022

The company partners with QURE and Curta to assess value of early identification in high-risk cohorts Excerpt from the Press Release: SAN DIEGO, Nov. 22, 2022 /PRNewswire/ — Biological Dynamics, an exosome-isolation technology and early disease detection diagnostic company, today announced that it has partnered with both QURE Healthcare and Curta to explore how the…

Read More

ONWARD’s Research Partner .NeuroRestore Publishes Groundbreaking Paper Identifying Neurons that Restore Walking after Paralysis

11/18/2022

Data from all nine participants in STIMO trial published in Nature Researchers identify specific neurons activated and remodeled by spinal cord stimulation that enable patients to walk Excerpt from the Press Release: EINDHOVEN, the Netherlands & LAUSANNE, Switzerland & BOSTON–(BUSINESS WIRE)–ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement,…

Read More

RSIP Vision Presents Successful Preliminary Results from Clinical Study of 2D-to-3D Knee Bones Reconstruction

11/02/2022

A tool for reconstruction of a 3D model of the knee from 2D X-ray images is being evaluated on clinical data at a leading medical center with promising results Excerpt from the Press Release: TEL AVIV, Israel and SAN JOSE, Calif., Oct. 27, 2022 /PRNewswire/ — RSIP Vision, an experienced developer of groundbreaking AI technologies for…

Read More